{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:42:35Z","timestamp":1769607755403,"version":"3.49.0"},"reference-count":37,"publisher":"Oncology Nursing Society (ONS)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Journal of Oncology Nursing"],"published-print":{"date-parts":[[2004,8,1]]},"DOI":"10.1188\/04.cjon.377-382","type":"journal-article","created":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T10:44:35Z","timestamp":1187865875000},"page":"377-382","source":"Crossref","is-referenced-by-count":16,"title":["Management of Patients Receiving Antithymocyte Globulin for Aplastic Anemia and Myelodysplastic Syndrome"],"prefix":"10.1188","volume":"8","author":[{"given":"Margaret F.","family":"Bevans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reem A.","family":"Shalabi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2007,2,14]]},"reference":[{"key":"E00001","doi-asserted-by":"crossref","unstructured":"Aivado, M., Rong, A., Stadler, M., Germing, U., Giagounidis, A., Strupp, C., et al. (2002). Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelo-dysplastic syndrome patients with a \u2018non-clonal\u2019 pattern of X-chromosome inactivation in bone marrow cells. <i>European Journal of Haematology, 68<\/i>, 210-216.","DOI":"10.1034\/j.1600-0609.2002.01625.x"},{"key":"E00002","unstructured":"Alessandrino, E.P., Amadori, S., Barosi, G., Cazzola, M., Grossi, A., Liberato, L.N., et al. (2002). Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes: A statement from the Italian Society of Hematology. <i>Haematologica, 87<\/i>, 1286-1306."},{"key":"E00003","unstructured":"Asano, Y., Maeda, M., Uchida, N., Yokoyama, T., Osaki, K., Shimoda, K., et al. (2001). Immunosuppressive therapy for patients with refractory anemia. <i>Annals of Hematology, 80<\/i>, 634-638."},{"key":"E00004","doi-asserted-by":"crossref","unstructured":"Bacigalupo, A., Brand, R., Oneto, R., Bruno, B., Socie, G., Passweg, J., et al. (2000). Treatment of acquired severe aplastic anemia: Bone marrow transplantation compared with immuno-suppressive therapy\u2014The European Group for Blood and Marrow Transplantation experience. <i>Seminars in Hematology, 37<\/i>, 69-80.","DOI":"10.1016\/S0037-1963(00)90031-3"},{"key":"E00005","doi-asserted-by":"crossref","unstructured":"Bacigalupo, A., Chaple, M., Hows, J., Van Lint, M.T., McCann, S., Milligan, D., et al. (1993). Treatment of aplastic anemia (AA) with antilymphocyte globulin (ALG) and methylpred-nisolone (MPred) with or without androgens: A randomized trial from the EBMT SAA working party. <i>British Journal of Haematology, 83<\/i>, 145-151.","DOI":"10.1111\/j.1365-2141.1993.tb04645.x"},{"key":"E00006","unstructured":"Bevans, M., Nunez, O., Wisch, L., & Chamberlain, C. (2001). Management of infusion related toxicities associates with high-dose antithymocyte globulin (ATG) [Abstract 1789]. <i>Blood, 98<\/i>(Pt. 1), 426a."},{"key":"E00007","doi-asserted-by":"crossref","unstructured":"Bielory, L., Gascon, P., Lawley, T.J., Neinhuis, A., Frank, M.M., & Young, N.S. (1986). Serum sickness and haematopoietic recovery with antithymocyte globulin in bone marrow failure patients. <i>British Journal of Haematology, 63<\/i>, 729-736.","DOI":"10.1111\/j.1365-2141.1986.tb07556.x"},{"key":"E00008","doi-asserted-by":"crossref","unstructured":"Bowen, D., Culligan, D., Jowitt, S., Kelsey, S., Mufti, G., Oscier, D., et al. (2003). Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. <i>British Journal of Haematology, 120<\/i>, 187-200.","DOI":"10.1046\/j.1365-2141.2003.03907.x"},{"key":"E00009","doi-asserted-by":"crossref","unstructured":"Champlin, R., Ho, W., & Gale, R.P. (1983). Antithymocyte globulin treatment in patients with aplastic anemia: A prospective randomized trial. <i>New England Journal of Medicine, 308<\/i>, 113-118.","DOI":"10.1056\/NEJM198301203080301"},{"key":"E00010","doi-asserted-by":"crossref","unstructured":"Dansey, R. (2000). Myelodysplasia. <i>Current Opinion in Oncology, 12<\/i>, 13-21.","DOI":"10.1097\/00001622-200001000-00003"},{"key":"E00011","doi-asserted-by":"crossref","unstructured":"Dean, N.C., Amend, W.C., & Matthay, M.A. (1987). Adult respiratory distress syndrome related to antilymphocyte globulin therapy. <i>Chest, 91<\/i>, 619-620.","DOI":"10.1378\/chest.91.4.619"},{"key":"E00012","doi-asserted-by":"crossref","unstructured":"Dearden, C., Foukaneli, T., Lee, P., Gordon-Smith, B.C., & Marsh, J.C. (1998). The incidence and significance of fevers during treatment with antithymocyte globulin for aplastic anemia. <i>British Journal of Haematology, 103<\/i>, 846-848.","DOI":"10.1046\/j.1365-2141.1998.01047.x"},{"key":"E00013","doi-asserted-by":"crossref","unstructured":"Di Bona, E., Rodeghiero, F., Bruno, B., Gabbas, A., Foa, P., Locasciulli, A., et al. (1999). Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anemia patients unresponsive to a first course of intensive immunosuppressive therapy. <i>British Journal of Haematology, 107<\/i>, 330-334.","DOI":"10.1046\/j.1365-2141.1999.01693.x"},{"key":"E00014","doi-asserted-by":"crossref","unstructured":"Docherty, B. (2002a). Cardiorespriatory physical assessment for the acutely ill: 1. <i>British Journal of Nursing, 11<\/i>, 750-758.","DOI":"10.12968\/bjon.2002.11.11.750"},{"key":"E00015","doi-asserted-by":"crossref","unstructured":"Docherty, B. (2002b). Cardiorespiratory physical assessment for the acutely ill: 2. <i>British Journal of Nursing, 11<\/i>, 800-807.","DOI":"10.12968\/bjon.2002.11.12.10302"},{"key":"E00016","doi-asserted-by":"crossref","unstructured":"Ferns, T., & Chojnacka, I. (2003). The causes of anaphylaxis and its management in adults. <i>British Journal of Nursing, 12<\/i>, 1006-1012.","DOI":"10.12968\/bjon.2003.12.17.11713"},{"key":"E00017","doi-asserted-by":"crossref","unstructured":"Frickhofen, N., Kaltwasser, J.P., Schrezenmeier, H., Raghavachar, A., Vogt, H.G., Herrmann, F., et al. (1991). Treatment of aplastic anemia with antilymphocyte globulin and methyl-prednisolone with or without cyclosporine. <i>New England Journal of Medicine, 324<\/i>, 1297-1304.","DOI":"10.1056\/NEJM199105093241901"},{"key":"E00018","doi-asserted-by":"crossref","unstructured":"Gaber, A.O., First, M.R., Tesi, R.J., Gaston, R.S., Mendez, R., Mulloy, L.L., et al. (1998). Results of the double-blinded, randomized, multi-center, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. <i>Transplantation, 66<\/i>, 29-37.","DOI":"10.1097\/00007890-199807150-00005"},{"key":"E00019","unstructured":"Genzyme Corporation. (2002). Thymoglobulin\u00ae (anti-thymocyte globulin [rabbit]) [Package insert]. Cambridge, MA: Author."},{"key":"E00020","doi-asserted-by":"crossref","unstructured":"Gorantla, V.S., Barker, J.H., Jones, J.W., Jr., Prabhune, K., Maldonado, C., & Granger, D.K. (2000). Immunosuppressive agents in transplantation: Mechanisms of action and current anti-rejection strategies. <i>Microsurgery, 20<\/i>, 420-429.","DOI":"10.1002\/1098-2752(2000)20:8<420::AID-MICR13>3.0.CO;2-O"},{"key":"E00021","doi-asserted-by":"crossref","unstructured":"Higgins, C. (2000). The risks associated with blood and blood product transfusion. <i>British Journal of Nursing, 10<\/i>, 2281-2290.","DOI":"10.12968\/bjon.2000.9.22.5415"},{"key":"E00022","doi-asserted-by":"crossref","unstructured":"Killick, S.B., Marsh, J.C., Booth, J.C., & Gordon-Smith, E.C. (1997). Liver function abnormality following treatment with antithymocyte globulin for aplastic anemia. <i>Bone Marrow Transplant, 19<\/i>, 249-251.","DOI":"10.1038\/sj.bmt.1700653"},{"key":"E00023","doi-asserted-by":"crossref","unstructured":"Killick, S.B., Mufti, G., Cavenagh, J.D., Mijovic, A., Peacock, J.L., Gordon-Smith, E.C., et al. (2003). A pilot study of antithymocyte globulin (ATG) in the treatment of patients with \u2018low-risk\u2019 myelodysplasia. <i>British Journal of Haematology, 120<\/i>, 679-684.","DOI":"10.1046\/j.1365-2141.2003.04136.x"},{"key":"E00024","doi-asserted-by":"crossref","unstructured":"Maillard, N., Foucher, P., Caillot, D., Durand, C., Sgro, C., & Camus, P. (1999). Transient pulmonary infiltrates during treatment with anti-thymocyte globulin. <i>Respiration, 66<\/i>, 279-282.","DOI":"10.1159\/000029374"},{"key":"E00025","doi-asserted-by":"crossref","unstructured":"Millar, M.M., & Grammar, L.C. (2000). Case reports of evaluation and desensitization for antithymocyte globulin hypersensitivity. <i>Annals of Allergy, Asthma and Immunology, 85<\/i>, 311-316.","DOI":"10.1016\/S1081-1206(10)62535-5"},{"key":"E00026","doi-asserted-by":"crossref","unstructured":"Molldrem, J.J., Leifer, E., Bahceci, E., Saunthararajah, Y., Rivera, M., Dunbar, C., et al. (2002). Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. <i>Annals of Internal Medicine, 137<\/i>, 156-163.","DOI":"10.7326\/0003-4819-137-3-200208060-00007"},{"key":"E00027","doi-asserted-by":"crossref","unstructured":"Murdock, D.K., Lawless, C.E., Collins, E.E, Huml, J.P., & Pifarre, R. (1987). ARDS following equine ATG therapy. <i>Chest, 92,<\/i> 578.","DOI":"10.1378\/chest.92.3.578"},{"key":"E00028","unstructured":"Pfizer Inc. (2002). Atgam\u00ae (lymphocyte immune globulin, antithymocyte globulin, equine) [Package insert]. New York: Author."},{"key":"E00029","doi-asserted-by":"crossref","unstructured":"Rosenfeld, S.J., Kimball, J., Vining, D., & Young, N.S. (1995). Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. <i>Blood, 85<\/i>, 3058-3065.","DOI":"10.1182\/blood.V85.11.3058.bloodjournal85113058"},{"key":"E00030","doi-asserted-by":"crossref","unstructured":"Shelton, B.K. (2003). Evidence-based care for the neutropenic patient with leukemia. <i>Seminars in Oncology Nursing, 19<\/i>, 133-141.","DOI":"10.1016\/S0749-2081(03)00026-3"},{"key":"E00031","doi-asserted-by":"crossref","unstructured":"Speck, B., Gluckman, E., Haak, H.L., & van Rood, J.J. (1977). Treatment of aplastic anemia by antilymphocyte globulin with and without allogeneic bone marrow infusion. <i>Lancet, 2<\/i>, 1145-1148.","DOI":"10.1016\/S0140-6736(77)91537-9"},{"key":"E00032","doi-asserted-by":"crossref","unstructured":"Speck, B., Gratwohl, A., Nissen, C., Leibundgut, U., Ruggero, D., Osterwalder, B., et al. (1981). Treatment of severe aplastic anaemia with antilymphocyte globulin or bone-marrow transplantation. <i>BMJ, 282<\/i>, 860-863.","DOI":"10.1136\/bmj.282.6267.860"},{"key":"E00033","doi-asserted-by":"crossref","unstructured":"Walton, G.D., & Gualtiere, R.J. (1998). Antithymocyte globulin-induced adult respiratory distress syndrome. <i>Archives of Internal Medicine, 158<\/i>, 1380.","DOI":"10.1001\/archinte.158.12.1380"},{"key":"E00034","doi-asserted-by":"crossref","unstructured":"Young, N.S. (1999). Acquired aplastic anemia. <i>JAMA, 282<\/i>, 271-278.","DOI":"10.1001\/jama.282.3.271"},{"key":"E00035","doi-asserted-by":"crossref","unstructured":"Young, N.S. (2002). Acquired aplastic anemia. <i>Annals of Internal Medicine, 136<\/i>, 534-546.","DOI":"10.7326\/0003-4819-136-7-200204020-00011"},{"key":"E00036","doi-asserted-by":"crossref","unstructured":"Young, N.S., & Maciejewski, J. (1997). The pathophysiology of acquired aplastic anemia. <i>New England Journal of Medicine, 336<\/i>, 1365-1372.","DOI":"10.1056\/NEJM199705083361906"},{"key":"E00037","doi-asserted-by":"crossref","unstructured":"Zomas, A., Marsh, J., Harrison, N., Hyer, S., Nussey, S., Knee, G., et al. (1995). Rapid progression of fibrosing alveolitis and thyrotoxicosis after antithymocyte globulin therapy for aplastic anemia. <i>Annals of Hematology, 71<\/i>, 49-51.","DOI":"10.1007\/BF01696232"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/V554182226887M6G.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:52:34Z","timestamp":1763754754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/8\/4\/management-patients-receiving-antithymocyte-globulin-aplastic-anemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,1]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,8,1]]}},"alternative-id":["V554182226887M6G"],"URL":"https:\/\/doi.org\/10.1188\/04.cjon.377-382","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"value":"1092-1095","type":"print"},{"value":"1538-067X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8,1]]}}}